Esophageal carcinoma: Towards targeted therapies
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with esophageal cancer are confronted with high mortality rates. Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), patients usually present at advanced stages, with treatment options traditionally involving chemotherapy in metastatic settings. With the comprehensive genomic characterization of esophageal cancers, targeted therapies are gaining interest and agents such as ramucirumab, trastuzumab and pembrolizumab are already being used for the treatment of EAC. CONCLUSIONS: Pembrolizumab has recently been FDA-approved for PD-L1 positive, locally advanced or metastatic ESCC. Despite comprehensive molecular characterization, however, available targed therapies for ESCC are still lagging behind. Herein, we discuss current trends towards more targeted therapies in esophageal cancers, taking into consideration unique features of ESCCs and EACs. Patients progressing on standard therapies should be subjected to genomic profiling and considered for clinical trials aimed at testing targeted therapies. Future targeted therapies may include CDK4/6 inhibitors, PARP inhibitors and inhibitors targeting the NRF2 and Wnt signaling pathways. Ultimately, optimized biomarker assays and next generation sequencing platforms may allow for the identification of subcategories of ESCC and EAC patients that will benefit from selective targeted therapies and/or combinations thereof.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, squamous carcinoma is the most common pathogenic form of esophageal cancer in China [18].Its growth rate and pathological changes are diferent from those of adenocarcinoma [19], so the patient may experience diverse symptoms and thus interpret them variously.”
From Symptom Experiences before Medical Help-Seeking and Psychosocial Responses of Patients with Esophageal Cancer: A Qualitative Study. (2023) · cites this paper as [19]
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, Jr., Al-Sarraf, M., Byhardt, R., Russell, A. H., Beitler, J. J., Spencer, S., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1623 · Cited by 1,957
A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., & Hennessy, T. P. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350702 · Cited by 1,950
Integrated genomic characterization of oesophageal carcinoma
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,821
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Research works printed but not linked: 1
- Available from: https://www.ascopost.com/issues/april-10-2019-supplement-conference-highlights-gugi-2019/keynote-181-in-esophageal-cancer/. Accessed 19 October 2019
Cited by
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer
Yao, Z., Yang, Y., Sun, M., He, Y., Liao, L., Chen, K., & Li, B. (2022) · Cancer Communications · doi:10.1002/cac2.12254 · Cited by 288
Advances and challenges in the treatment of esophageal cancer
He, S., Xu, J., Liu, X., & Zhen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.008 · Cited by 287
m6A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1
Guo, H., Wang, B., Xu, K., Nie, L., Fu, Y. S., Wang, Z., Wang, Q., Wang, S., & Zou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.553045 · Cited by 140
Zhu, P., Yu, H., Zhou, K., Bai, Y., Qi, R., & Zhang, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01618-7 · Cited by 57
Research on esophageal cancer: With personal perspectives from studies in China and Kenya
Yang, C. S., & Chen, X. L. (2020) · International Journal of Cancer · doi:10.1002/ijc.33421 · Cited by 58
Molecular mechanisms associated with chemoresistance in esophageal cancer
Lohan-Codeço, M., Barambo-Wagner, M. L., Nasciutti, L. E., Pinto, L. F. R., Costa, N. M. D., & Palumbo, A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04131-6 · Cited by 67
Li, Z.-C., Sun, Y., Lai, M.-Y., Zhou, Y.-X., & Qiu, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108790 · Cited by 50
Progress on the study of the anticancer effects of artesunate (Review)
Yang, X., Zheng, Y., Liu, L., Huang, J., Wang, F., & Zhang, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.13011 · Cited by 52
Shen, L., Xia, M. H., Deng, X., Ke, Q., Zhang, C., Peng, F., Dong, X., & Luo, Z. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00517-5 · Cited by 45
Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer
Mao, C., Zeng, X., Zhang, C., Yang, Y., Xiao, X., Luan, S., Zhang, Y., & Yuan, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.612451 · Cited by 42
He, X., Zhou, Y., Chen, W., Zhao, X., Duan, L., Zhou, H., Li, M., Yin, Y., Zhao, J., Guo, Y., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02636-3 · Cited by 42
Targeted therapy for upper gastrointestinal tract cancer: current and future prospects
Rosenbaum, M. W., & González, R. S. (2020) · Histopathology · doi:10.1111/his.14244 · Cited by 32
Wang, Z., Wang, D., Wang, F., Ren, C., Tan, Q., & Li, Y. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01021-1 · Cited by 29
DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90β
Zhou, L., Yao, N., Yang, L., Liu, K., Qiao, Y., Huang, C., Du, R., Yeung, Y. T., Liu, W., Cheng, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112445 · Cited by 32
Zhang, L., Li, L., Chen, X., Yuan, S., Xu, T., Zhao, W., Li, M., Wang, F., Hoffman, R. M., & Jia, L. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154493 · Cited by 31
Wang, Y., Zhao, Q.-W., Sun, Z.-Y., Lin, H.-P., Xu, X., Cao, M., Fu, Y., Zhao, X., Ma, X., & Ye, Q. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76096 · Cited by 27
Su, W., Hu, H., Ding, Q., Wang, M., Zhu, Y., Zhang, Z., Geng, Z., Lin, S., & Zhou, P. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00898-0 · Cited by 29
Recent advances of m6A methylation modification in esophageal squamous cell carcinoma
Zhang, X., Lü, N., Wang, L., Wang, Y., Li, M., Zhou, Y., Cui, M., Zhang, M., & Zhang, L. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02132-2 · Cited by 23
Pang, J., He, P., Yang, C., Meng, P., Xie, W. Q., Li, J., Li, Y., & Xiao, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.722601 · Cited by 22
Zheng, W., Chen, C., Yu, J., Jin, C., & Han, T. (2021) · BMC Cancer · doi:10.1186/s12885-021-08030-0 · Cited by 21
Weng, W.-C., Huang, C., Su, C., Mukundan, A., Karmakar, R., Chen, T., Avhad, A. R., Chou, C., & Wang, H. (2025) · Diagnostics · doi:10.3390/diagnostics15131686 · Cited by 20
Profiles of autophagy-related genes in esophageal adenocarcinoma
Zhu, L., Dong, L., Feng, M., Yang, F., Jiang, W., Huang, Z., Liu, F., Wang, L., Wang, G., & Li, Q. (2020) · BMC Cancer · doi:10.1186/s12885-020-07416-w · Cited by 22
Shen, S., Liang, J., Liang, X., Wang, G., Feng, B., Guo, W., Guo, Y., & Dong, Z. (2021) · Cancer Science · doi:10.1111/cas.15184 · Cited by 20
Wang, X., Liu, Y., Lu, Y., Chen, S., Xing, Y., Yang, H., Wang, X., Zhang, Y., Pan, T., Li, J., et al. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.2016942 · Cited by 18
Chen, L., Fang, B., Qiao, L., & Zheng, Y. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2203.03050 · Cited by 18
Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review
Acharya, R. K., Mahapatra, A., Verma, H. K., & Bhaskar, L. V. (2023) · Current Oncology · doi:10.3390/curroncol30110691 · Cited by 20
Naseri, A., Salehi‐Pourmehr, H., Majidazar, R., Seraji, P., Rezazadeh‐Gavgani, E., Zehtabi, M., Kiani-Kezbin, H., Salehnia, F., Hassannezhad, S., Kamanaj, A. H., et al. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00721-y · Cited by 16
Cheng, J., Ma, H., Yan, M., Zhang, Z., & Xing, W. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110448 · Cited by 16
Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma
Kadian, L. K., Arora, M., Prasad, C. P., Pramanik, R., & Chauhan, S. S. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02763-x · Cited by 18
He, S., Zhao, C., Tao, H., Sheng, W., Gao, R., Liu, X., & Zhen, Y. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2063454 · Cited by 14
Eshkiki, Z. S., Mansouri, F., Karamzadeh, A. R., Namazi, A., Heydari, H., Akhtari, J., Tabaeian, S. P., & Akbari, A. (2024) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2024/1239661 · Cited by 17
Knockdown of NOLC1 Inhibits PI3K-AKT Pathway to Improve the Poor Prognosis of Esophageal Carcinoma
Kong, F., Shang, Y., Diao, X., Huang, J., & Liu, H. (2021) · Journal of Oncology · doi:10.1155/2021/9944132 · Cited by 13
Yang, B., Chen, Q., Wan, C., Sun, S., Zhu, L., Zhao, Z., Zhong, W., & Wang, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.709486 · Cited by 14
Li, X., Zhang, J., Wu, Y., Ma, C., Wei, D., Pan, L., & Cai, L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13371 · Cited by 13
Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects
Sabatelle, R. C., Colson, Y. L., Sachdeva, U. M., & Grinstaff, M. W. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00246 · Cited by 15
Neutrophil Extracellular Traps in Digestive Cancers: Warrior or Accomplice
Chen, Y., Han, L., Qiu, X., Wang, G., & Zheng, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766636 · Cited by 14
Gao, Y., Shen, L., Dong, T., Yang, X. L., Cui, H., Guo, Y., Ma, Y., Kong, P., Cheng, X., Zhang, L., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03489-2 · Cited by 13
Ma, J., Luo, Y., Liu, Y., Chen, C., Chen, A., Liang, L., Wang, W., & Song, Y. (2022) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2023.27.1.61 · Cited by 12
Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Jin, Z., Shen, J., Wang, C., Chen, D., Zhang, B., Zhang, J., Ajani, J. A., Bennouna, J., Chao, J., Yoon, H. H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2804 · Cited by 15
Jiang, S., Qiu, Y., Wang, Z., Ji, Y., Zhang, X., Yan, X., & Zhan, Z. (2021) · Journal of Oncology · doi:10.1155/2021/4451533 · Cited by 14
IDO1 facilitates esophageal carcinoma progression by driving the direct binding of NF-κB and CXCL10
Yao, W., Cui, X., Peng, H., Zhang, Y., Jia, X., Wu, S., & Zhao, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01689-3 · Cited by 10
Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes
Lopes, N., Correia, M. P., Henrique, R., & Jerónimo, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103522 · Cited by 13
Zhang, Q., Wu, T., Han, Y., Zheng, Z., & Zhang, Y. (2022) · Current Medical Science · doi:10.1007/s11596-022-2587-3 · Cited by 10
Khan, I. R., Sadida, H. Q., Hashem, S., Singh, M. K., Macha, M. A., Akil, A. S. A.-S., Khurshid, I., & Bhat, A. A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116873 · Cited by 13
ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis
Yao, L.-H., Wu, P., Yao, F.-Y., Huang, B., Zhong, F.-M., & Wang, X.-Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-89628-3 · Cited by 11
Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction
Grillo, F., Mastracci, L., Saragoni, L., Vanoli, A., Limarzi, F., Gullo, I., Ferro, J., Paudice, M., Parente, P., & Fassan, M. (2020) · Pathologica · doi:10.32074/1591-951x-164 · Cited by 10
Chen, H., Zheng, B., Xue, S., & Chen, C. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s258680 · Cited by 10
Qi, W., Li, R., Li, L., Li, S., Zhang, H., & Tian, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4015 · Cited by 10
Role of ursolic acid in preventing gastrointestinal cancer: recent trends and future perspectives
Chauhan, A. P. S., Pathak, V. M., Yadav, M., Chauhan, R., Babu, N., Chowdhary, M., Ranjan, A., Mathkor, D. M., Haque, S., Tuli, H. S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405497 · Cited by 12
miR-488-5p promotes esophageal squamous cell carcinoma progression by suppressing the P53 pathway
Su, C., Liu, W., Jiang, T., & Liu, J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1448 · Cited by 8
Zhang, W., Zhang, P., Jiang, J., Peng, K., Shen, Z., & Kang, M. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-948 · Cited by 9
Luo, J., Tian, Z., Zhou, Y., Xiao, Z., Park, S. Y., Sun, H., Zhuang, T., Wang, Y., Li, P., & Zhao, X. (2023) · Cancer Science · doi:10.1111/cas.15807 · Cited by 11
Pang, M., Xie, X., Zhang, Y., Laster, K. V., Liu, K., & Kim, D. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780011 · Cited by 9
Li, L., Liu, X., Huang, J. Z., Liu, Y., Huang, L., & Feng, Y. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-870 · Cited by 9
COL8A1 Regulates Esophageal Squamous Carcinoma Proliferation and Invasion Through PI3K/AKT Pathway
Hu, J., Li, P., Dan, Y., Chen, Z., Lu, Y., Chen, X., & Yan, S. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14370-x · Cited by 8
Anushree, U., Shetty, S., Aranjani, J. M., Kumar, R., & Bharati, S. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01655-1 · Cited by 9
Hassan, S., Johnson, C., Ponna, S., Scofield, D., Awasthi, N., & von Holzen, U. W. (2024) · Cancers · doi:10.3390/cancers16183175 · Cited by 8
Tian, X., Hou, Y., Guo, J., Wu, H., Nie, L., Wang, H., Zhang, Y., & Lv, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1096386 · Cited by 9
Statins as Potential Therapeutics for Esophageal Cancer
Hassanabad, A. F., & Wong, J. V. S. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00648-4 · Cited by 8
Zhu, L., Wang, J., Zhang, Q., Xia, T., Hu, S., Yao, W., & Li, W. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-214 · Cited by 8
lncRNA SSTR5-AS1 Predicts Poor Prognosis and Contributes to the Progression of Esophageal Cancer
Hu, Y., Mao, N., Zheng, W., Hong, B., & Deng, X. (2023) · Disease Markers · doi:10.1155/2023/5025868 · Cited by 8
Survival outcomes in esophageal cancer patients with a prior cancer
Pan, D., Xu, W., Gao, X., Yiyang, F., Shuai, W., & Zhu, G. (2021) · Medicine · doi:10.1097/md.0000000000024798 · Cited by 8
Hu, R., Bi, R., Lianyong, J., Yang, X., Zhong, Y., & Xie, X. (2021) · Journal of Cancer · doi:10.7150/jca.57814 · Cited by 8
Ye, Z., Xu, Z., Zeng, F.-Y., Tang, Z.-Q., & Zhou, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.934275 · Cited by 8
RNF6 activates TGF-β1/c-Myb pathway to promote EMT in esophageal squamous cell carcinoma
Cheng, J., Wu, K., Yang, Q., Zhu, Z., & Zhao, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1081333 · Cited by 7
RGS16 regulates Hippo-YAP activity to promote esophageal cancer cell proliferation and migration
Zhang, Y., Zhu, Q. J., Cao, X., & Ni, B. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.033 · Cited by 8
Ultrasound-stimulated microbubbles contributes to radiotherapy in esophageal carcinoma
Fu, C., Shi, J., Su, X., Feng, S., & Wang, S. (2021) · Biochemistry and Cell Biology · doi:10.1139/bcb-2021-0061 · Cited by 7
Weidle, U. H., Sela, T., Brinkmann, U., & Niewoehner, J. (2022) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20320 · Cited by 8
Liu, J., Shao, J., Zhang, C., Qin, G., Liu, J., Li, M., Wu, P., Zhao, X., & Zhang, Y. (2021) · European Journal of Immunology · doi:10.1002/eji.202149441 · Cited by 6
verma, H., Panda, P., & Bhaskar, L. V. (2023) · Onco · doi:10.3390/onco3030010 · Cited by 6
Xu, T., Yuan, Y., He, C., & Yang, K. (2021) · Medical Science Monitor · doi:10.12659/msm.927850 · Cited by 6
Targeted therapy in esophageal cancer
Hassan, S., Makuru, V., & von Holzen, U. W. (2021) · Digestive Medicine Research · doi:10.21037/dmr-21-16 · Cited by 6
Ge, H., Zhang, L., Ma, X., Li, W., & Li, S. (2023) · European Journal of Cancer Care · doi:10.1155/2023/6506917 · Cited by 5
Bioengineered Approaches for Esophageal Regeneration: Advancing Esophageal Cancer Therapy
Kim, J.-S., Nam, H., Kim, E. C., Jeong, H., & Lee, S. (2025) · Bioengineering · doi:10.3390/bioengineering12050479 · Cited by 7
Shang, Q.-X., Kong, W.-L., Huang, W., Xiao, X., Hu, W.-P., Yang, Y., Zhang, H., Yang, L., Yuan, Y., & Chen, L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1079795 · Cited by 6
Shen, Z., Zhang, P., Zhang, W., Luo, F., Xu, H., Chen, S., & Kang, M. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01049-5 · Cited by 5
RetractedLi, B., Zhang, J., Yin, Y., Li, Y., Chen, Y., Zhao, X., Li, A., Zhao, L., Li, M., Wang, Z., et al. (2024) · Frontiers of Medicine · doi:10.1007/s11684-024-1062-x · Cited by 5
Richter, F., Baratay, A., Röder, C., Egberts, J., Kalthoff, H., Becker, T., & Sebens, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082674 · Cited by 5
Yang, H., Wang, K., Li, Y., Li, S., Yuan, L., & Ge, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.783752 · Cited by 5
Jaffe, D. H., Gricar, J., DeCongelio, M., & Mackie, D. S. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14334 · Cited by 5
Su, Y., Huang, C., Chen, Y., Lin, Q., & Chen, Z. (2024) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2024.3452983 · Cited by 5
Yu, X.-W., She, P., Chen, F.-S., Chen, Y.-Y., Zhou, S. Y., Wang, X., Lin, X.-R., Liu, Q., Huang, Z., & Qiu, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-11890-x · Cited by 4
Zhang, X., Xu, C., Wang, C., Pei, Y., He, M. Y., Wan, Z., Hou, J. W., & Wang, L. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10280-8 · Cited by 4
Xie, L., Zhang, Y., Niu, X., Jiang, X., Kang, Y., Diao, X., Fang, J., Yu, Y., & Yao, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524439 · Cited by 12
Tang, L., Wang, L., Tao, Y., Xu, T., Zhang, L., & Shu, Y. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-1567 · Cited by 4
Prognostic signature of esophageal adenocarcinoma based on pyroptosis-related genes
Li, G., He, R., Liu, J., He, J., Fu, Z.-W., Yang, L., Ma, J., Yang, L., Zhou, H., Zeng, J., et al. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01196-x · Cited by 4
Yan, Z., Xu, T., Lu, J., Wu, Z., Li, X., Xu, J., Guo, W., & Dong, Z. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153963 · Cited by 4
[Retracted] Alpha Protein Kinase 2 Promotes Esophageal Cancer via Integrin Alpha 11
Ainiwaer, J., Zhang, L., Niyazi, M., Awut, E., Zheng, S., Sheyhidin, I., & Dai, J. H. (2022) · BioMed Research International · doi:10.1155/2022/7676582 · Cited by 4
RetractedThe Expression and Therapeutic Potential of Checkpoint Kinase 2 in Laryngeal Squamous Cell Carcinoma
Tian, Y., Wang, Y., Xu, S., Guan, C., Zhang, Q., & Li, W. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s245267 · Cited by 6
Meng, Y., Feng, H., Li, B., Xie, Y., Li, Z., Li, Z., & Li, X. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70017 · Cited by 3
Qi, L. W., Xie, Y., Wang, W. N., Liu, J., Yang, K. G., Chen, K., Luo, C. H., Jing, F., & Hu, J. M. (2024) · PeerJ · doi:10.7717/peerj.18080 · Cited by 5
Molecular subtyping and precision therapy for esophageal cancer
Pei, G., Liang, Z., Gu, B., Shi, L., Liu, Z., & Gao, S. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240105 · Cited by 3
Lin, A., Song, L., Wang, Y., Yan, K., & Tang, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15039 · Cited by 3
Zhang, Z.-F. (2023) · Medical Science Monitor · doi:10.12659/msm.938512 · Cited by 4
Zhou, J., Wu, J., Wu, G., Huang, J., Zhang, Y., Che, J., Zhu, K., Geng, J., & Fan, Q. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109788 · Cited by 3
Vu, T. H. N., Kikuchi, O., Ohashi, S., Saito, T., Ida, T., Nakai, Y., Cao, Y., Yamamoto, Y., Kondo, Y., Mitani, Y., et al. (2023) · Cancer Science · doi:10.1111/cas.15966 · Cited by 2
Li, Y., Ma, L., & Li, P. (2024) · Biochemical Genetics · doi:10.1007/s10528-023-10585-5 · Cited by 3
Could venom-derived therapeutics resolve treatment resistance in refractory EAC?
Freuville, L., Matthys, C., Gilliaux, Q., D'Hondt, L. A., & Gillet, J. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.03.007 · Cited by 2
Targeting the Mevalonate Pathway for Treating Esophageal Cancer
Wong, J. V. S., & Hassanabad, A. F. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00644-8 · Cited by 2
Metadata
- Authors
- Fatehi Hassanabad, A., Chehade, R., Breadner, D., & Raphael, J.
- Affiliations
- Western University (CA)
- Venue
- Cellular Oncology
- Published
- 2019-12-17
- Volume
- 43
- Issue
- 2
- Pages
- 195-209
- ISSN
- 1570-5870 (ISSN-L)
- 2211-3428
- 2211-3436
- PMC
- PMC12990719
- OpenAlex
- W2994654968
- Cited by
- 158
- References
- 83
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 29 · 2023: 20 · 2022: 44 · 2021: 29 · 2020: 14
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cellular Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- esophageal squamous cell carcinoma, esophageal adenocarcinoma, targeted therapy, pembrolizumab, PD-L1, ramucirumab, trastuzumab, CDK4/6 inhibitors, PARP inhibitors, Nrf2 signaling, Wnt signaling, genomic profiling, biomarkers, metastatic esophageal cancer
- MeSH terms
- Adenocarcinoma, Carcinoma, Squamous Cell, Enzyme Inhibitors, Esophageal Neoplasms, Humans, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.